HBK Sorce Advisory LLC Invests $2.53 Million in Medpace Holdings, Inc. $MEDP

Key Points

• HBK Sorce Advisory bought 4,309 Medpace shares worth approximately $2.53 million during the second quarter. Institutional investors collectively own 77.98% of the company.
• Medpace exceeded quarterly expectations, reporting $4.25 in earnings per share versus the $3.98 consensus and $707.33 million in revenue, up 17.2% year over year.
• Analysts maintain a consensus “Hold” rating with an average price target of $584.18, while Medpace shares opened at $578.50; insiders have sold roughly $38.0 million of stock over the past 90 days.

HBK Sorce Advisory LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 4,309 shares of the company's stock, valued at approximately $2,533,000.

Several other institutional investors and hedge funds also recently made changes to their positions in MEDP. Elyxium Wealth LLC purchased a new position in Medpace in the 4th quarter worth approximately $30,000. Allied Private Wealth LLC bought a new position in Medpace in the 2nd quarter valued at approximately $31,000. Basecamp Wealth Advisors LLC boosted its stake in Medpace by 187.5% during the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company's stock valued at $33,000 after purchasing an additional 45 shares during the last quarter. Quarry LP purchased a new stake in Medpace during the 3rd quarter valued at $35,000. Finally, Bayban purchased a new stake in Medpace during the 4th quarter valued at $44,000. Institutional investors own 77.98% of the company's stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $578.50 on Monday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The company has a market cap of $16.15 billion, a PE ratio of 33.91, a price-to-earnings-growth ratio of 2.58 and a beta of 1.15. The company has a 50 day simple moving average of $536.23 and a two-hundred day simple moving average of $491.58.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the previous year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on MEDP shares. BMO Capital Markets boosted their price target on Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a research note on Friday, July 24th. Wall Street Zen cut Medpace from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Jefferies Financial Group cut Medpace from a "buy" rating to a "hold" rating and increased their price objective for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Finally, Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $584.18.

Insider Transactions at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total value of $690,121.80. Following the completion of the transaction, the director directly owned 12,275 shares in the company, valued at approximately $7,430,916.75. This represents a 8.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 67,195 shares of company stock worth $37,989,998. 20.50% of the stock is currently owned by insiders.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source